Novel approaches to new therapies for hepatitis B virus infection

Rohit Loomba, T. Jake Liang

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Hepatitis B is one of the most prevalent viral diseases in the world. It leads to chronic liver disease in 10% of infected individuals, putting them at an increased risk for liver-related morbidity and mortality from complications of cirrhosis and hepatocellular carcinoma. Despite the success of universal hepatitis B vaccination in many countries, this disease remains a major public health problem, resulting in more than 500,000 deaths per year. Although the current therapy for chronic hepatitis B (CHB) is effective, it is not optimal; novel approaches to the management of CHB are needed. An improved understanding of virus-host interactions, advances in gene therapy, the development of molecular therapies targeted at different stages of the hepatitis B virus life cycle, and new insights into various approaches of immune modulation will lead to the development of better therapeutic agents for the management of CHB. These advances herald a new era of combination therapy. In this review, we will discuss emerging therapies and potential mechanisms, and highlight the promises and pitfalls of these new treatment strategies.

Original languageEnglish (US)
Pages (from-to)1-15
Number of pages15
JournalAntiviral Therapy
Issue number1
StatePublished - 2006
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Novel approaches to new therapies for hepatitis B virus infection'. Together they form a unique fingerprint.

Cite this